FGP
TARS icon

Freestone Grove Partners’s Tarsus Pharmaceuticals TARS Stock Holding History

Freestone Grove Partners’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.3M Buy
+68,389
New +$4.37M 0.03% 354
2025
Q1 		– Sell
-7,921
Closed -$439K – 779
2024
Q4 		$439K Buy
+7,921
New +$360K 0.01% 398

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Freestone Grove Partners's TARS Position: Q2 2026 in Review

Freestone Grove Partners opened a new position in Tarsus Pharmaceuticals (TARS) in Q2 2026: 68,389 shares worth $4.3M. The stake represents 0.03% of the portfolio and ranks #354 among its holdings. This is a return to the name: Freestone Grove Partners previously reported a position in TARS as recently as Q4 2024.

Freestone Grove Partners first reported a position in TARS in Q4 2024 and has held it in 2 quarters since. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • Freestone Grove Partners held 68,389 shares of Tarsus Pharmaceuticals worth $4.3M as of Q2 2026.
  • Tarsus Pharmaceuticals was a new Freestone Grove Partners position in Q2 2026.
  • Tarsus Pharmaceuticals made up 0.03% of Freestone Grove Partners's portfolio in Q2 2026, its #354 holding.
  • Freestone Grove Partners first reported a position in Tarsus Pharmaceuticals in Q4 2024 and has held it in 2 quarters since.
  • 257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.